BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 26407672)

  • 1. Addressing challenges of heterogeneous tumor treatment through bispecific protein-mediated pretargeted drug delivery.
    Yang Q; Parker CL; McCallen JD; Lai SK
    J Control Release; 2015 Dec; 220(Pt B):715-26. PubMed ID: 26407672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretargeting with bispecific fusion proteins facilitates delivery of nanoparticles to tumor cells with distinct surface antigens.
    Yang Q; Parker CL; Lin Y; Press OW; Park SI; Lai SK
    J Control Release; 2017 Jun; 255():73-80. PubMed ID: 28363519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multivalent interactions between streptavidin-based pretargeting fusion proteins and cell receptors impede efficient internalization of biotinylated nanoparticles.
    Parker CL; Yang Q; Yang B; McCallen JD; Park SI; Lai SK
    Acta Biomater; 2017 Nov; 63():181-189. PubMed ID: 28870833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoscale drug delivery for targeted chemotherapy.
    Xin Y; Huang Q; Tang JQ; Hou XY; Zhang P; Zhang LZ; Jiang G
    Cancer Lett; 2016 Aug; 379(1):24-31. PubMed ID: 27235607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
    Varshosaz J; Farzan M
    World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretargeted radioimmunotherapy of cancer: progress step by step.
    Boerman OC; van Schaijk FG; Oyen WJ; Corstens FH
    J Nucl Med; 2003 Mar; 44(3):400-11. PubMed ID: 12621007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanocarriers for cancer-targeted drug delivery.
    Kumari P; Ghosh B; Biswas S
    J Drug Target; 2016; 24(3):179-91. PubMed ID: 26061298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanomedicine: An effective tool in cancer therapy.
    Aftab S; Shah A; Nadhman A; Kurbanoglu S; Aysıl Ozkan S; Dionysiou DD; Shukla SS; Aminabhavi TM
    Int J Pharm; 2018 Apr; 540(1-2):132-149. PubMed ID: 29427746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved Targeting of Cancers with Nanotherapeutics.
    Foster C; Watson A; Kaplinsky J; Kamaly N
    Methods Mol Biol; 2017; 1530():13-37. PubMed ID: 28150194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor extracellular acidity-activated nanoparticles as drug delivery systems for enhanced cancer therapy.
    Du JZ; Mao CQ; Yuan YY; Yang XZ; Wang J
    Biotechnol Adv; 2014; 32(4):789-803. PubMed ID: 23933109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting liposomes toward novel pediatric anticancer therapeutics.
    Federman N; Denny CT
    Pediatr Res; 2010 May; 67(5):514-9. PubMed ID: 20118828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system.
    Kibria G; Hatakeyama H; Harashima H
    Arch Pharm Res; 2014 Jan; 37(1):4-15. PubMed ID: 24272889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretargeting: A Path Forward for Radioimmunotherapy.
    Cheal SM; Chung SK; Vaughn BA; Cheung NV; Larson SM
    J Nucl Med; 2022 Sep; 63(9):1302-1315. PubMed ID: 36215514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoparticle approaches to combating drug resistance.
    Moon JH; Moxley JW; Zhang P; Cui H
    Future Med Chem; 2015 Aug; 7(12):1503-10. PubMed ID: 26334205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances and advantages of nanomedicine in the pharmacological targeting of hyaluronan-CD44 interactions and signaling in cancer.
    Skandalis SS; Gialeli C; Theocharis AD; Karamanos NK
    Adv Cancer Res; 2014; 123():277-317. PubMed ID: 25081534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperthermia approaches for enhanced delivery of nanomedicines to solid tumors.
    Frazier N; Ghandehari H
    Biotechnol Bioeng; 2015 Oct; 112(10):1967-83. PubMed ID: 25995079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretargeted imaging and radioimmunotherapy of cancer using antibodies and bioorthogonal chemistry.
    van de Watering FC; Rijpkema M; Robillard M; Oyen WJ; Boerman OC
    Front Med (Lausanne); 2014; 1():44. PubMed ID: 25593917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.